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ABSTRACT 
 
 
Background 
Obesity is a risk factor for osteoarthritis and total hip/knee 
joint replacement and can also lead to poorer outcomes 
following surgical interventions. Self-management programs 
are a recommended approach for addressing clinical 
features of osteoarthritis and obesity. 
 
Aims 
This study investigates the relative efficacy of the Flinders 
chronic condition self-management program versus 
treatment as usual in obese patients with hip or knee 
osteoarthritis on a knee/hip joint replacement waiting list. 
 
Methods  
Obese (Body Mass Index or BMI≥30) osteoarthritis patients 
on a knee/hip joint replacement waiting list will be assessed 
for study eligibility. 95 consented patients will provide 80 
per cent power to detect an effect size of 0.6 in the primary 
outcome measure of quality of life at 6 months and 10 
months, at α=10 per cent level. A randomised sequence, 
stratified by gender and obesity class will be generated and 
administered by a computer-based system. Health-related 
quality of life outcomes will be collected using Short Form 
SF-36 and OAKHQOL at 6 and 10 months pre- and post-
operatively. The main analysis will investigate differences in 
SF-36 scores between the intervention and treatment as 
usual groups on an intention-to-treat basis. Linear mixed 
effect models will be used to analyse outcome data. 
 
Conclusion 
This study is designed to provide robust and transparent 
findings including randomisation sequence generation, 
allocation concealment and implementation and will 
therefore provide much needed quality evidence in the field 
of self-management and osteoarthritis.
1
 The Flinders 
Program has not been used in this type of patient cohort 
before and since it has been proven a successful self-
management tool for other chronic conditions in Australian 
communities, the results of this study will add valuable 
knowledge to the chronic condition management. 
 
Key Words 
Obesity, osteoarthritis, chronic condition self-management, 
randomised controlled trial, quality of life 
 
What this study adds:  
1. What is known about this subject?  
Obesity is a risk factor for osteoarthritis and hip/knee joint 
replacement. Self-management is a recommended 
approach for addressing both obesity and osteoarthritis. 
 
2. What new information is offered in this study? 
The Flinders chronic condition self-management support is 
tailored to target obese patients with osteoarthritis in order 
to improve health-related quality of life. 
 
3. What are the implications for research, policy, or 
practice?  
With the prevalence of obesity and osteoarthritis 
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increasing, finding an approach to address both is critical. 
 
Background 
Osteoarthritis is characterised by the inflammation of the 
synovial membrane of joints and the progressive 
breakdown of joint cartilage, resulting in pain and stiffness,
2
 
and can lead to significant disability and functional 
limitations (e.g. walking).
2
 The increasing prevalence of 
osteoarthritis is well documented in epidemiological 
reports, for example, in Australia there was a rise from 7.5 
per cent in 2008 in the osteoarthritis prevalence to 8.1 per 
cent in 2014.
3
 As life expectancy increases, the prevalence 
of osteoarthritis is expected to increase.
4,5
  
 
The most prevalent extrinsic risk factor for osteoarthritis is 
obesity which is also the most modifiable risk factor.
6
 There 
is a positive association between obesity and both hip and 
knee osteoarthritis.
7,8
 Although total knee or hip joint 
replacement (TKR/THR) is the most effective treatment for 
improving function and reducing pain in patients with 
advanced knee or hip osteoarthritis, poorer outcomes are 
experienced for obese patients.
9
 The impact of obesity on 
functional outcome, pain and complications following 
TKR/THR have been well studied with obesity being 
reported as an indicator of higher rates of complications, 
and lower improvement in pain and functional outcomes, 
although the latter with some controversy.
10-16
 Studies 
evaluating the impact of obesity on Health-Related Quality-
of-Life (HRQoL) outcomes of TKR/THR are on the other 
hand, limited and lack methodological rigour.
17-20
 
 
Chronic disease self-management programs have shown to 
have some benefits for both physical and psychological 
aspects of chronic conditions and associated risk factors.
21-23
 
Self-management has been used in the treatment for 
osteoarthritis,
6,23
 and is also a recommended method of 
addressing obesity which may require changing habits, and 
therefore well-developed self-regulatory skills, consistency 
and timeliness.
24
 A well-developed self-management 
support program may help obese osteoarthritis patients 
improve HRQoL by controlling the chronic condition, 
improving their lives and potentially assisting in their weight 
loss. A previous systematic review has suggested that self-
management programs offer modest benefits for people 
with osteoarthritis; but these findings were tentative due to 
mostly low quality studies e.g. a lack of transparency in 
reporting randomisation methods or concealment of 
allocation. This highlights the need for more robust studies 
to be reported according to the Consort guidelines.
1
 This 
proposed study will add to the evidence-base through 
rigorous reporting of all aspects of the study including 
randomisation procedures, and to the best of our 
knowledge it will be the first study to evaluate a self-
management program in people with both osteoarthritis 
and obesity.  
 
While different types of self-management programs have 
been used, they generally aim to increase active 
participation of the person with the condition in monitoring 
their health, making decisions about care, or both. Self-
management support programs mostly come in either of 
two types: disease-specific patient education programs or 
lay-led programs. Disease-specific programs provide 
organised learning experiences designed to facilitate the 
adoption of health-promoting behaviours for one particular 
condition, and are usually delivered by health professionals. 
These programs have been criticised for the many people 
dealing with multiple morbidities. Lay-led group programs 
aim to improve participants’ confidence in managing both 
their chronic conditions, in partnership with health 
professionals, and their lives.
22
  
 
Flinders program was developed based on Stanford 
program. A major feature of the Flinders Program is that it 
addresses both patient behaviours and clinician behaviours 
that are necessary for sustained gain in health outcomes. 
The Program provides a generic set of tools and a structured 
process that enables health workers and patients to 
collaboratively assess self-management behaviours, identify 
problems, set goals, and develop individual care plans 
covering key self-care, medical, psycho-social and carer 
issues.
 22
 
 
The Flinders Chronic Condition Management Program, 
developed by Battersby et al. is an individualised generic 
self-management support program which has the flexibility 
to be combined with targeted disease-specific 
interventions.
22,25
 The Flinders Program has been validated 
and successfully implemented for various target groups 
including patients with obstructive sleep apnoea, and 
Vietnam veterans with co-morbid alcohol misuse and 
psychiatric and medical conditions.
22,25-27
 It has also been 
implemented in Aboriginal communities with complex 
chronic conditions such as diabetes, heart disease and 
respiratory illness.
28
 The benefits experienced by a diverse 
cohort of sub-populations from the Flinders Program, 
reflect its generic properties for a broad range of disorders 
and risk factors. It may be that the Flinders Program can 
provide a mechanism for patients who suffer from 
osteoarthritis and co-occurring obesity to better manage 
their conditions and subsequently experience 
improvements in quality of life.  
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Therefore, the aim of this study is to evaluate the efficacy of 
the self-management support Flinders Program in 
improving Health-Related Quality of Life for obese hip or 
knee osteoarthritis patients on a total knee or hip joint 
replacement waiting list, in six months of intervention. A 
further aim is to determine whether self-management 
competency is associated with weight loss for this cohort of 
patients. 
 
Method 
Study design  
Evaluating the impact of the Flinders Program on HRQoL in 
obese osteoarthritis patients is a two-group randomised, 
parallel design with patients on a total knee or hip joint 
replacement waiting list registered at the Repatriation 
General Hospital in Adelaide, South Australia. The study will 
recruit 94 patients over a 6-month enrolment period 
starting July 2015 and follow-ups at 6-month and 10-month. 
Eligible patients will be randomised to either a control 
group receiving usual care or an intervention group 
receiving the Flinders Program for six months. The study has 
received approval from the Southern Adelaide Clinical 
Human Research Ethics Committee (SAC HREC), and was 
registered with the Australian New Zealand Clinical Trials 
Registry (ACTRN12615000674538). 
 
Eligibility for participation 
Patients will be invited to participate if they meet the 
following criteria: Have a BMI of 30 kg/m² or above; have 
been on the knee or hip joint replacement waiting list due 
to osteoarthritis and willingly provide signed informed 
consent form to participate in the study. Patients with the 
following criteria will be excluded from the study: have a 
BMI of under 30 kg/m², have an emotional or neurological 
condition that would pre-empt their ability or willingness to 
participate in the study including mental illness, intellectual 
disability, drug or alcohol abuse, as reported to the 
hospital’s waiting list by the patient’s GP; have had a 
surgery within the past three months; have dementia. 
Patients who have a pacemaker or Implantable Cardioverter 
Defibrillator (ICD) will be excluded from the body fat 
measurement test.  
Participant recruitment 
Participants will be drawn from osteoarthritis patients who 
are on the knee or hip joint replacement waiting list of 
Repatriation General Hospital. Eligible participants will 
initially be identified through patient information provided 
by the staff at the Repatriation General hospital, and sent 
an invitation letter to participate in the study along with the 
patient information sheet. The project officer will then 
make a follow-up phone call to individual patients to 
ascertain their willingness to participate in the study. For 
patients who agree to be in the study a visit time to obtain 
written consent and enrolment will then be arranged. 
 
Sample size  
The primary research question is: Does the Flinders Program 
plus treatment as usual improve HRQoL for obese 
osteoarthritis patients on a total knee or hip joint 
replacement waiting list compared to treatment as usual 
only? The Flinders Program is a safe intervention and little 
harm in the widespread application of such a program is 
expected. In fact, some benefits such as self-management 
competency might be gained, even if the Flinders Program 
does not directly reduce obesity or improve all aspects of 
HRQoL. Therefore, any penalties of a type I error will be 
nominal. In contrast, the consequences of a Type II error 
may have a more negative impact since a safe, inexpensive, 
and possibly effective intervention may be missed. In such 
exploratory studies, there is a strong rationale for using a 
less stringent statistical significance (i.e. α=0.10).
29
 This 
design parameter is frequently used in exploratory or phase 
II studies including those involving biological and 
psychotherapeutic interventions.
30,31
 Also, as the control 
group in this study will receive usual care, which only 
includes general information and no further attention, a 
clinically meaningful difference with moderate effect size is 
expected in favour of intervention group. Therefore, based 
on a type I error rate of 10 per cent, power of 80 per cent, 
two-tailed test, to detect an effect size of 0.6, 36 
participants in each arm are required. Stata13 was used to 
calculate the sample size.
32
 With an anticipated dropout 
rate of 30 per cent, we would need to recruit 47 
participants in each group of the study, resulting in a total 
sample size of 94 participants. 
 
Randomisation and allocation concealment 
Following enrolment of participants, baseline assessments 
will be conducted. Then participants will be randomly 
assigned to one of two groups, either control or 
intervention with a 1:1 allocation ratio. Randomisation will 
be blocked to ensure approximately similar group sizes, 
using varying block sizes to protect concealment. To achieve 
balance in each arm on observed patient characteristics, 
randomisation will also be stratified on gender and BMI 
groups. BMI groups will be stratified as 30-34.9 (obese), 35-
39.9 (severely obese), 40 and above (morbidly obese). A 
biostatistician will independently generate stratified 
blocked randomisation sequences using Stata 14.1 
(StataCorp, College Station, TX, USA) statistical software and 
deliver to the clinical trial pharmacy at Repatriation General 
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Hospital. Once baseline measurements are taken for each 
participant, an independent staff member will assign the 
next random allocation by emailing the gender and BMI 
group of the participant to the clinical trial pharmacy, and 
receiving the allocation group.  
 
Treatments 
The control group will receive the usual care from 
physiotherapists, general practitioners and community 
services (e.g. RDNS – Royal District Nursing Service) after 
attending an information session at the hospital where a 
nurse from the hospital and an expert from Arthritis 
Australia provide guidance to manage their chronic 
condition. 
 
Participants in the intervention group will receive the usual 
care as well as the Flinders Program which will be delivered 
by a nurse who is trained at FHBHRU (Flinders Human 
Behaviour and Health Research Unit) prior to the start of 
the study. The Flinders Program will be delivered in an 
individual format in one face-to-face session and fortnightly 
follow up phone calls for six months, on a day and time 
agreed between the nurse and the patient. The Flinders 
Program education leader will regularly supervise the 
delivery of the program. During the initial face-to-face 
session of the Flinders Program, the participant will fill out 
the self-rated Partners in Health Scale (PIH). The Partners in 
Health (PIH) scale is a short and precise tool comprising of 
12 self-rated items to reflect the definition of chronic 
condition self-management.
22
 The intervention 
administering nurse will then explore the same questions in 
the form of a Cue and Response Interview (C&R) rating from 
her perspective, shared with the patient. Problem and Goals 
assessment (P&G) tool is then used to determine patient-
identified problems and formulated goals to address those 
problems. These will be used to produce a fully negotiated 
care plan including identified priorities issues, management 
aims, agreed interventions, responsibilities and review 
dates. The initial session takes approximately one hour. 
After the initial session, participants will be provided follow-
ups 2-4 weekly for six months to monitor progress, provide 
feedback and motivation, and problem solving training.  
 
Blinding 
Baseline measurements will be obtained before 
randomisation and are therefore free of any assignment-
related bias. Since participants are informed that the 
intervention is a self-management support program, they 
will therefore be aware of whether or not they are receiving 
such a program. Participant information sheets also inform 
participants of potential benefits of both control and 
intervention programs, and therefore equipoise nature of 
the study. Participants will be advised not to discuss their 
allocation with data collection staff. Clinicians delivering the 
Flinders Program will be un-blinded. Random assignments 
will be concealed from data collection staff and will be 
recorded in a separate database accessed from a separate 
computer. Data analysts will be blinded to treatment 
allocation by the use of non-informative labels for the 
treatment group variable. 
 
Measures 
Demographic data including age as a continuous variable, 
gender, living arrangements (alone, with partner, with 
children, other), work status (unemployed, retired, full-time 
job, part-time job), and education level (primary school, 
secondary school, Bachelor degree, postgraduate) will be 
collected. In addition to demographic data, the following 
measures will be collected. The measures are presented in 
Table 1. 
 
Outcome Measures 
Outcome measures will be administered at baseline 
assessment, pre-surgery (approximately 6-months post-
baseline) and 10-month post-baseline visits. In order to 
detect changes in Health-Related Quality of Life during 
intervention and at follow-ups, HRQoL will be quantified as 
the primary outcome measure. In order to thoroughly 
assess HRQoL, the use of both generic and disease-specific 
instruments is recommended. The generic 36-item Short-
Form Health Survey (SF-36) questionnaire will measure 
HRQoL in eight domains of physical functioning, role 
limitations due to physical problems, bodily pain, general 
health perception, vitality, social limitation owing to 
emotional problems, role limitations due to emotional 
problems and mental health. The disease-specific OAKHQOL 
(Osteoarthritis of Knee or Hip Quality of Life) measures 
HRQoL in five domains of physical activities, mental health, 
pain, social support, social functioning.
33
 This instrument is 
a 43-item scale with common problems for osteoarthritis 
patients, where each item is rates on a 1-10 Likert scale, and 
has been validated in previous studies.
34,35
 As pain and 
function are both very important for patients, these aspects 
of quality of life will be measured as part of both SF-36 and 
OAKHQOL. 
 
One of the secondary outcomes is self-management 
competency which will be measured using Partners in 
Health (PIH) Scale of the Flinders Program. In conjunction 
with patient assessment and goal setting processes, it is an 
important part of Flinders Program, and is structurally valid 
instrument for measuring chronic condition self-
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management in an Australian community.
36
 The PIH is a 12-
item questionnaire based on the seven principles of self-
management.
37
 Changes in self-management competency 
will be assessed by comparison of changes in the control 
group and the intervention group between baseline and 
follow up and between groups over time. This will examine 
whether the changes in self-management competency that 
take place can be attributed to the Flinders Program. PIH 
has been validated in previous studies.
37
 
 
Obesity is another secondary outcome which has to be 
monitored. The scale of obesity is commonly measured 
using BMI, an index based on height and weight 
information. However, it is now known that BMI as an index 
of obesity has a number of limitations such as its inability to 
distinguish between fat mass and fat-free mass.
38
 
Nevertheless, BMI still provides a simple and 
straightforward method of measuring obesity. In order to 
balance the limitations of BMI, two simply achievable 
central obesity measurements, namely Waist Circumference 
(WC) and Waist-to-Height Ratio (WHtR) will be taken.
38
 In 
order to have a more accurate body composition 
measurement to compensate for limitation of 
anthropometric measures of BMI, WC and WHtR in 
estimating body composition and obesity,
39
 whole body fat 
percentage will also be measured using a MF-BIA device 
(IMPᵗᵐ SFB7 Bio Impedance Spectroscopy-ImpediMed, a 
validated measurement tool). The IMPᵗᵐ SFB7 is a single 
channel, tetra polar bioimpedance spectroscopy (BIS) that 
scans 256 frequencies between 4 kHz and 1000 kHz. The 
device utilises Cole modelling with Hanai mixture theory to 
determine total body water (TBW), extracellular fluid (ECF) 
and intracellular fluid (ICF) from impedance data. Fat-free 
mass (FFM) and fat mass (FM) are then calculated on the 
device. People with a pacemaker or Implantable 
Cardioverter Defibrillator (ICD) are not recommended to be 
tested using this device, and are therefore excluded from 
this test. 
 
Questionnaires will be mailed out if participants do not 
attend their follow up appointments to ensure maximum 
return rate. 
 
Process Evaluation 
Intervention process will be evaluated using Cue & 
Response, and Problems & Goals scores which will be 
collected from intervention participants at baseline and 6 
months follow-ups or pre-operation. These scores present 
the level of compliance as well as the effects of the 
intervention program on the specified problems and goals.  
 
Study Management 
Monitoring Adverse Events 
It is not anticipated that this study will result in any adverse 
emotional, psychological or physical events. However, 
should any adverse events arise as a result of the study; the 
patient will be referred to the appropriate health 
professional for further care. In the event of any adverse 
events, these will be reported to the Southern Adelaide 
Clinical Human Research Ethics Committee (SAC HREC) 
immediately. 
 
Data Management  
Data will be entered by a staff member. Data files will be 
held on a secure database and backed up daily. 
 
Study Drop-outs 
Participants will be advised that they can voluntarily 
withdraw from the study at any time. Where a participant 
withdraws from the study, the reason(s) will be enquired 
and will be documented in the study results. 
 
Treatment Drop-outs 
Non-compliance participants in the intervention group will 
not be considered drop-out to reflect the efficacy of the 
program in real world. The level of treatment adherence for 
each participant will contribute to data analyses in the 
following section. 
 
Data Analyses 
All statistical analyses will be conducted using Stata 14.1 
(StataCorp, College Station, TX, USA) software. The primary 
analysis will be intent-to-treat (ITT) to identify any 
statistically significant differences in SF-36 scores over time 
for the treatment and follow-up period, between Flinders 
Program and the usual care groups. To account for 
participant attrition and lack of treatment adherence, an ‘as 
treated’ and ‘per protocol’ analysis will also be conducted. 
The ‘as treated’ approach will help establish associations 
between clusters of participant characteristics and 
treatment outcomes from an observational perspective. The 
‘per protocol’ analysis will be used to evaluate treatment 
efficacies for participants who adhere to their assigned 
treatment protocol. Secondary measures will be analysed 
using the same approach as outlined above. 
 
Linear mixed models will be used for repeated measures of 
primary and secondary continuous and categorical 
outcomes. Fixed effects in models will include treatment 
group, time points of baseline, 6 and 12 month follow-up 
and interaction between group and time. Random effects 
will be at the study participant level and represent an 
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upward or downward shift in the outcome measure from an 
overall regression line and the rate of change over time. 
Linear combinations of regression coefficients will be tested 
for treatment group effect at the completion of the 
intervention period and for maintenance effects, and 
estimates will be presented along with 95 per cent 
confidence intervals. Predicted estimates of treatment 
outcomes at each time point will be calculated using fitted 
models of the data in order to examine patterns of 
individual change within each group. 
 
The reporting of this trial will comply with CONSORT 
(Consolidated Standards of Reporting Trials) guidelines for 
nonpharmacological treatments.
40
 
 
Qualitative Component 
After the intervention period, approximately 8 to 12 
participants from the intervention group will be invited to 
be interviewed about their perceptions and experiences of 
the Flinders Program. Purposeful sampling will ensure 
reflecting a range of individual experiences including 
treatment adherers and non-adherers. Interviews will be 
transcribed and documented, and then analysed using 
thematic analysis. 
 
Baseline Results 
Participant recruitment and flow  
The flow of participants through each stage of the study is 
shown in Figure 1. Participants were recruited from a total 
of 218 patients on the hip or knee joint replacement waiting 
list. The most common reason for study exclusion was 
residential distance from the hospital, making it difficult to 
attend visits.  
 
 
Baseline characteristics 
Baseline socio-demographics for n=95 participants are 
presented in Table 2. Minimum age of participants was 45 
and maximum 84. There were 20 participants younger than 
age of 60, 10 of whom have full-time or part-time jobs. 
 
Baseline characteristics for n=95 participants are presented 
in Table 3. When stratifying BMI groups, there were 33 (34.7 
per cent) obese, 41 (43.2 per cent) severely obese and 21 
(22.1 per cent) morbidly obese. 
 
Discussion 
The design of this trial is guided by ethical considerations, 
and the study was approved by the Southern Adelaide 
Health Service Ethics committee. 
 
Self-management support is a recommended treatment for 
both osteoarthritis and obesity, and to our best knowledge, 
its impact on HRQoL of patients with both obesity and 
osteoarthritis has not been studied in a robust and 
transparent study before. This study will contribute key 
information to treatment of obese osteoarthritis patients 
before a knee or hip joint replacement surgery. The one-on-
one nature of the Flinders Program will also provide 
valuable information about dealing with multiple chronic 
conditions as many of the studied cohort have multiple 
chronic conditions. The qualitative interviews will further 
explore the treatment effects from the participants’ 
perspective and complement the quantitative outcomes in 
drawing an extensive view of the intervention in practice. 
 
A key strength of this study is the broad inclusion criteria 
and the fact that a considerable number of participants 
have comorbidities such as other chronic conditions, e.g. 
diabetes, asthma, etc., which will increase the external 
validity of the findings of this study. Another strength of this 
study includes the robustness in design and transparency in 
reporting the details of the design, enrolment, 
randomisation and other details, so that the results of this 
study could be reliable. 
 
We stratified our randomisation for gender and BMI groups. 
Other potential cofounders such as comorbidity could be 
considered in future studies. However, due to the relatively 
small sample size in our study, further stratification could 
potentially lead to treatment group imbalance. Future large 
scale studies should also investigate sub-populations 
including complex comorbid conditions (e.g. a patient with 
knee osteoarthritis, depression and tobacco dependence). 
In addition, a further limitation is that this study will be 
conducted at a public hospital with a higher likelihood of 
treating patients with low socio-economic status, which 
might affect the outcomes.  
 
 
Conclusion 
The rationale and protocol for a randomised controlled trial 
to investigate the impacts of the self-management support 
Flinders Program on Health-Related Quality of Life of obese 
osteoarthritis patients was described. To our knowledge, 
this is the first randomised controlled trial to evaluate self-
management support for this cohort. The data collected in 
this trial will provide a high-quality basis for future 
application of self-management support in clinics. 
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Table 1: Measurements 
  Intervention period Maintenance period 
Measurements Baseline 6 months 10 months 
Demographics      
HRQOL       
 SF-36   
 OAKHQOL    
Self-Management       
 PIH   
Obesity        
 BMI   
 WC    
 WHtR   
 %BF   
Intervention participants only: 
Cue & Response score     
Problems & Goals score     
 
Table 2: Baseline socio-demographics 
 
Socio-demographic data N=95 
Age (years) 66.89 (8.64) 
Female 58 (61) 
Living arrangement 
Living alone 32 (30) 
Living with partner / children 56 (60) 
Other 6 (10) 
Work status 
Retired / unemployed 78 (82) 
Full-time job 7 (8) 
Part-time job 9 (9) 
Qualification 
Primary school 8 (8) 
Secondary school 61 (64) 
Undergraduate 10 (11) 
Postgraduate 7 (7) 
Other 9 (9) 
 Data are mean (SD), or n (%). 
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Table 3: Baseline clinical characteristics 
 
Baseline characteristics N=95 
BMI 37.29 (4.75) 
WC 118.74 (13.10) 
WHtR 0.73 (0.07) 
%BF 39.5 (8.81) 
SF36  
Vitality 35.86 (20.18) 
Physical function 27.00 (18.22) 
Bodily pain 24.23 (14.75) 
General health perception 56.02 (22.33) 
Total physical score 31.57 (6.74) 
Physical role 34.61 (22.42) 
Emotional role 58.07 (31.19) 
Social role 49.47 (32.36) 
Mental health 65.07 (21.31) 
Total mental score 45.71 (12.54) 
OAKHQOL  
Physical Activity 36.63 (17.27) 
Mental health 55.16 (25.54) 
Pain 27.11 (21.03) 
Social support 68.00 (22.51) 
Social activities 59.28 (26.11) 
Professional activities 49.67 (34.99) 
Spouse relation 50.18 (35.73) 
Sexual activities 46.00 (40.53) 
Self-management (PIH) 77.97 (12.23) 
 Data are mean (SD), or n (%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 307 
 
[AMJ 2016;9(9):297–307] 
 
 
Figure 1: Participant flow 
 
